Aprea Therapeutics, Inc. Research and Development in Process
Aprea Therapeutics, Inc. (APRE) reported Research and Development in Process of $76.02 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-08-10
- Aprea Therapeutics, Inc. research and development in process for the quarter ending 2022-12-31 was $0.00.
- Aprea Therapeutics, Inc. research and development in process for the quarter ending 2022-09-30 was $0.00.
- Aprea Therapeutics, Inc. research and development in process for the quarter ending 2022-06-30 was $76.02M.
- Aprea Therapeutics, Inc. research and development in process for fiscal 2022 was $76.02M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $76.02M derived: sum of 3 quarters · filed 2023-08-10 | $76.02M 10-K · filed 2023-03-30 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $76.02M derived: sum of 2 quarters · filed 2023-08-10 | $76.02M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $76.02M 10-Q · filed 2023-08-10 | $76.02M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |